Abstract
Background
Calprotectin (S100A8/S100A9), a heterodimeric EF-hand Ca2+ binding protein, are abundant in cytosol of neutrophils and are involved in inflammatory processes and several cancerous pathogens.
Objective
The purpose of the present systematic review is to evaluate the pro- and anti-tumorigenic functions of calprotectin and its relation to inflammation.
Materials and methods
We conducted a review of studies published in the Medline (1966–2018), Scopus (2004–2018), ClinicalTrials.gov (2008–2018) and Google Scholar (2004–2018) databases, combined with studies found in the reference lists of the included studies.
Results
Elevated levels of S100A8/S100A9 were detected in inflammation, neoplastic tumor cells and various human cancers. Recent data have explained that many cancers arise from sites of infection, chronic irritation, and inflammation. The inflammatory microenvironment which largely includes calprotectin, has an essential role on high producing of inflammatory factors and then on neoplastic process and metastasis.
Conclusion
Scientists have shown different outcomes in inflammation, malignancy and apoptosis whether the source of the aforementioned protein is extracellular or intracellular. These findings are offering new insights that anti-inflammatory therapeutic agents and anti-tumorigenic functions of calprotectin can lead to control cancer development.
Similar content being viewed by others
References
Nishikawa Y, Kajiura Y, Lew JH, Kido JI, Nagata T, Naruishi K. Calprotectin induces IL-6 and MCP-1 production via toll-like receptor 4 signaling in human gingival fibroblasts. J Cell Physiol. 2017;232(7):1862–71.
Moore BW, McGregor D. Chromatographic and electrophoretic fractionation of soluble proteins of brain and liver. J Biol Chem. 1965;240(1647):53–60.
Shahsavari A, Azad M, Mobarra N, Chegini KG, Gheibi N. Calprotectin pegylation enhanced its physical and structural properties. Protein J. 2016;35(5):363–70.
Koy M, Hambruch N, Hussen J, Pfarrer C, Seyfert H-M, Schuberth H-J. Recombinant bovine S100A8 and A9 enhance IL-1β secretion of interferon-gamma primed monocytes. Vet Immunol Immunopathol. 2013;155(3):162–70.
Abtin AEL, Glaser R, Gmeiner R, Mildner M, et al. The antimicrobial heterodimer S100A8/S100A9 (calprotectin) is upregulated by bacterial flagellin in human epidermal keratinocytes. J Invest Dermatol. 2010;130:2423–30.
Strupat K, Rogniaux H, Van Dorsselaer A, Roth J, Vogl T. Calcium-induced noncovalently linked tetramers of MRP8 and MRP14 are confirmed by electrospray ionization-mass analysis. J Am Soc Mass Spectrom. 2000;11(9):780–8.
Hongyan Chen CX. Qing’e Jin, Zhihua Liu. Review Article S100 protein family in human cancer. Am J Cancer Res. 2014;4(2):89–115.
Loser K, Vogl T, Voskort M, Lueken A, Kupas V, Nacken W, et al. The Toll-like receptor 4 ligands Mrp8 and Mrp14 are crucial in the development of autoreactive CD8+ T cells. Nat Med. 2010;16(6):713–7.
Ghavami S, Tehrani FK, Hashemi M, Zarif MN. Possible involvement of a specific cell surface receptor for calprotectin-induced apoptosis in colon adenocarcinoma and carcinam cell lines (SW742 and HT29/219). J Sci Islamic Repub Iran. 2004;15(1):3–12.
Poullis A, Foster R, Mendall MA, Fagerhol MK. Emerging role of calprotectin in gastroenterology. J Gastroenterol Hepatol. 2003;18(7):756–62.
Nilsen T, Sunde K, Larsson A. A new turbidimetric immunoassay for serum calprotectin for fully automatized clinical analysers. J Inflamm. 2015;12(1):45.
Rumman N, Sultan M, El-Chammas K, Goh V, Salzman N, Quintero D, et al. Calprotectin in cystic fibrosis. BMC Pediatr. 2014;14(1):133.
Vincent Z, Hornby S, Ball S, Sanders G, Ayling RM. Faecal calprotectin as a marker for oesophago-gastric cancer. Ann Clin Biochem. 2015;52(6):660–4.
Goyette J, Geczy CL. Inflammation-associated S100 proteins: new mechanisms that regulate function. Amino Acids. 2011;41(4):821–42.
Fritz G, Botelho HM, Morozova-Roche LA, Gomes CM. Natural and amyloid self-assembly of S100 proteins: structural basis of functional diversity. FEBS J. 2010;277(22):4578–90.
Thomas Vogl ALG, Ludmilla A. Morozova-Roche. Pro-Inflammatory. S100A8 and S100A9 proteins: self-assembly into multifunctional native and amyloid complexes. Int J Mol Sci. 2012;13:2893–917.
Völkers M, Rohde D, Goodman C, Most P. S100A1: a regulator of striated muscle sarcoplasmic reticulum Ca2+. BioMed Res Int. 2010;2010:1–10.
Imani M, Bahrami Y, Jaliani HZ, Ardestani SK. In Solution cation-induced secondary and tertiary structure alterations of human calprotectin. Protein J. 2014;33(5):465–73.
Asghari H, Chegini KG, Amini A, Gheibi N. Effect of poly and mono-unsaturated fatty acids on stability and structure of recombinant S100A8/A9. Int J Biol Macromol. 2016;84:35–42.
Gheibi N, Asghari H, Chegini K, Sahmani M, Moghadasi M. The role of calcium in the conformational changes of the recombinant S100A8/S100A9. Mol Biol. 2016;50(1):136–42.
Santamaria-Kisiel L, Rintala-Dempsey AC, Shaw GS. Calcium-dependent and-independent interactions of the S100 protein family. Biochem J. 2006;396(2):201–14.
Korndörfer IP, Brueckner F, Skerra A. The crystal structure of the human (S100A8/S100A9) 2 heterotetramer, calprotectin, illustrates how conformational changes of interacting α-helices can determine specific association of two EF-hand proteins. J Mol Biol. 2007;370(5):887–98.
Gagnon DM, Brophy MB, Bowman SE, Stich TA, Drennan CL, Britt RD, et al. Manganese binding properties of human calprotectin under conditions of high and low calcium: X-ray crystallographic and advanced electron paramagnetic resonance spectroscopic analysis. J Am Chem Soc. 2015;137(8):3004–16.
Robinson MJ, Tessier P, Poulsom R, Hogg N. The S100 family heterodimer, MRP-8/14, binds with high affinity to heparin and heparan sulfate glycosaminoglycans on endothelial cells. J Biol Chem. 2002;277(5):3658–65.
Viemann D, Strey A, Janning A, Jurk K, Klimmek K, Vogl T, et al. Myeloid-related proteins 8 and 14 induce a specific inflammatory response in human microvascular endothelial cells. Blood. 2005;105(7):2955–62.
NematiNiko F, Chegini KG, Asghari H, Amini A, Gheibi N. Modifying effects of carboxyl group on the interaction of recombinant S100A8/A9 complex with tyrosinase. Biochim Biophys Acta (BBA) Proteins Proteom. 2017;1865(3):370–9.
Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products. Circulation. 2006;114(6):597–605.
Tesarova P, Kalousova M, Zima T, Tesar V. HMGB1, S100 proteins and other RAGE ligands in cancer-markers, mediators and putative therapeutic targets. Biomed Papers. 2016;160(1):1–10.
Yatime L, Betzer C, Jensen Rasmus K, Mortensen S, Jensen Poul H, Andersen Gregers R. The structure of the RAGE: S100A6 complex reveals a unique mode of homodimerization for S100 proteins. Structure. 2016;24(12):2043–52.
Kang JH, Hwang SM, Chung IY. S100A8, S100A9 and S100A12 activate airway epithelial cells to produce MUC5AC via extracellular signal-regulated kinase and nuclear factor-κB pathways. Immunology. 2015;144(1):79–90.
Ma L, Sun P, Zhang J-C, Zhang Q, Yao S-L. Proinflammatory effects of S100A8/A9 via TLR4 and RAGE signaling pathways in BV-2 microglial cells. Int J Mol Med. 2017;40(1):31–8.
Yatime L, Betzer C, Jensen RK, Mortensen S, Jensen PH, Andersen GR. The structure of the RAGE: S100A6 complex reveals a unique mode of homodimerization for S100 proteins. Structure. 2016;24(12):2043–52.
Leclerc E, Heizmann C. The importance of Ca2+/Zn2 + signaling S100 proteins and RAGE in translational medicine. Front Biosci (Sch ed). 2011;3:1232–62.
Heizmann C, Ackermann G, Galichet A. Pathologies involving the S100 proteins and RAGE. calcium signalling and disease. Springer. 2007;45:93–138.
Yatime L, Andersen GR. Structural insights into the oligomerization mode of the human receptor for advanced glycation end-products. FEBS J. 2013;280(24):6556–68.
Vogl T, Tenbrock K, Ludwig S, Leukert N, Ehrhardt C, Van Zoelen MA, et al. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat medicine. 2007;13(9):1042–9.
Ehrchen JM, Sunderkötter C, Foell D, Vogl T, Roth J. The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J Leukoc Biol. 2009;86(3):557–66.
Bhattacharyya S, Varga J. Endogenous ligands of TLR4 promote unresolving tissue fibrosis: Implications for systemic sclerosis and its targeted therapy. Immunol Lett. 2018;195:9–17.
Joosten LA, Abdollahi-Roodsaz S, Dinarello CA, O’neill L, Netea MG. Toll-like receptors and chronic inflammation in rheumatic diseases: new developments. Nat Rev Rheumatol. 2016;12(6):344–57.
Xin X, Zeng X, Gu H, Li M, Tan H, Jin Z, et al. CD147/EMMPRIN overexpression and prognosis in cancer: a systematic review and meta-analysis. Sci Rep. 2016;6:1–12.
Kaushik DK, Hahn JN, Yong VW. EMMPRIN, an upstream regulator of MMPs, in CNS biology. Matrix Biol. 2015;44:138–46.
Yamamoto M, Sakaguchi M, Motoyama A, Huh N-h, Tsuboi R, Hibino T. Identification of a novel receptor for S100A8 and its possible involvement in abnormal proliferation. J Dermatol Sci. 2013;69(2):e5.
Hojilla CV, Wood GA, Khokha R. Inflammation and breast cancer. Metalloproteinases as common effectors of inflammation and extracellular matrix breakdown in breast cancer. Breast Cancer Res. 2008;10(2):205–12.
Nabeshima K, Iwasaki H, Koga K, Hojo H, Suzumiya J, Kikuchi M. Emmprin (basigin/CD147): matrix metalloproteinase modulator and multifunctional cell recognition molecule that plays a critical role in cancer progression. Pathol Int. 2006;56(7):359–67.
Kanekura T, Chen X. CD147/basigin promotes progression of malignant melanoma and other cancers. J Dermatol Sci. 2010;57(3):149–54.
Hibino T, Sakaguchi M, Miyamoto S, Yamamoto M, Motoyama A, Hosoi J, Shimokata T, Ito T, Tsuboi R, Huh N. S100A9 is a novel ligand of EMMPRIN that promotes melanoma metastasis. Cancer Res. 2013;73:172–83.
Leukert N, Sorg C, Roth J. Molecular basis of the complex formation between the two calcium-binding proteins S100A8 (MRP8) and S100A9 (MRP14). Biol Chem. 2005;386(5):429–34.
Alexaki VI, May AE, Fujii C, Ungern-Sternberg SNV, Mund C, Gawaz M, et al. S100A9 induces monocyte/macrophage migration via EMMPRIN. Thromb Haemost. 2017;117(03):636–9.
Yurchenko V, Constant S, Eisenmesser E, Bukrinsky M. Cyclophilin–CD147 interactions: a new target for anti-inflammatory therapeutics. Clin Exp Immunol. 2010;160(3):305–17.
Yu X-L, Hu T, Du J-M, Ding J-P, Yang X-M, Zhang J, et al. Crystal structure of HAb18G/CD147 implications for immunoglobulin superfamily homophilic adhesion. J Biol Chem. 2008;283(26):18056–65.
Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255):539–45.
Munn LL. Cancer and inflammation. Wiley Interdiscip Rev Syst Biol Med. 2017;9(2):e1370.
Marelli G, Sica A, Vannucci L, Allavena P. Inflammation as target in cancer therapy. Curr Opin Pharmacol. 2017;35:57–65.
Mose M, Kang Z, Raaby L, Iversen L, Johansen C. TNFα-and IL-17A-mediated S100A8 expression is regulated by p38 MAPK. Exp Dermatol. 2013;22(7):476–81.
Munn L. Cancer and inflammation. Wiley Interdiscip Rev Syst Biol Med. 2017;9(2):1–19.
Yamanishi Y, Boyle DL, Rosengren S, Green DR, Zvaifler NJ, Firestein GS. Regional analysis of p53 mutations in rheumatoid arthritis synovium. Proc Natl Acad Sci. 2002;99(15):10025–30.
Rodríguez LAG, Huerta-Alvarez C. Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. Epidemiology. 2001;12(1):88–93.
Friis S, Riis AH, Erichsen R, Baron JA, Sørensen HT. Low-dose aspirin or nonsteroidal anti-inflammatory drug use and colorectal cancer RiskA population-based, case–control study NSAID use and colon cancer risk. Ann Intern Med. 2015;163(5):347–55.
Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–7.
Muranushi C, Olsen CM, Pandeya N, Green AC. Aspirin and nonsteroidal anti-inflammatory drugs can prevent cutaneous squamous cell carcinoma: a systematic review and meta-analysis. J Investig Dermatol. 2015;135(4):975–83.
Park JH, Watt DG, Roxburgh CS, Horgan PG, McMillan DC. Colorectal cancer, systemic inflammation, and outcome. Ann Surg. 2016;263(2):326–36.
Kim ER, Chang DK. Colorectal cancer in inflammatory bowel disease: the risk, pathogenesis, prevention and diagnosis. World J Gastroenterol. 2014;20(29):9872–81.
Raimondi S, Lowenfels AB, Morselli-Labate AM, Maisonneuve P, Pezzilli R. Pancreatic cancer in chronic pancreatitis; aetiology, incidence, and early detection. Best Pract Res Clin Gastroenterol. 2010;24(3):349–58.
Bleeker MC, Visser PJ, Overbeek LI, van Beurden M, Berkhof J. Lichen sclerosus: incidence and risk of vulvar squamous cell carcinoma. Cancer Epidemiol Prev Biomark. 2016;25(8):1224–30.
Reid BJ, Li X, Galipeau PC, Vaughan TL. Barrett’s oesophagus and oesophageal adenocarcinoma: time for a new synthesis. Nat Rev Cancer. 2010;10(2):87–101.
Bald T, Quast T, Landsberg J, Rogava M, Glodde N, Lopez-Ramos D, et al. Ultraviolet-radiation-induced inflammation promotes angiotropism and metastasis in melanoma. Nature. 2014;507(7490):109–13.
Morrison WB. Inflammation and cancer: a comparative view. J Vet Intern Med. 2012;26(1):18–31.
Sgambato A, Cittadini A. Inflammation and cancer: a multifaceted link. Eur Rev Med Pharmacol Sci. 2010;14(4):263–8.
El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142(6):1264–73.
Rubinstein PG, Aboulafia DM, Zloza A. Malignancies in HIV/AIDS: from epidemiology to therapeutic challenges. AIDS (Lond Engl). 2014;28(4):453–65.
Husted L, Jensen TK, Olsen SN, Mølbak L. Examination of equine glandular stomach lesions for bacteria, including Helicobacter spp. by fluorescence in situ hybridisation. BMC Microbiol. 2010;10(84):1–8.
Feller L, Lemmer J. Oral squamous cell carcinoma: epidemiology, clinical presentation and treatment. J Cancer Ther. 2012;3:263–8.
Dematei A, Fernandes R, Soares R, Alves H, Richter J, Botelho MC. Angiogenesis in Schistosoma haematobium-associated urinary bladder cancer. Apmis. 2017;125(12):1056–62.
Zhang X, Mosser D. Macrophage activation by endogenous danger signals. J Pathol. 2008;214(2):161–78.
Oppenheim JJ, Yang D. Alarmins: chemotactic activators of immune responses. Curr Opin Immunol. 2005;17(4):359–65.
Nukui T, Ehama R, Sakaguchi M, Sonegawa H, Katagiri C, Hibino T, et al. S100A8/A9, a key mediator for positive feedback growth stimulation of normal human keratinocytes. J Cell Biochem. 2008;104(2):453–64.
Leclerc EFG, Weibel M, Heizmann CW, Galichet A. S100B and S100A6 differentially modulate cell survival by interacting with distinct RAGE (receptor for advanced glycation end products) immunoglobulin domains. J Biol Chem. 2007;282:31317–31.
Boyd JH, Kan B, Roberts H, Wang Y, Walley KR. S100A8 and S100A9 mediate endotoxin-induced cardiomyocyte dysfunction via the receptor for advanced glycation end products. Circ Res. 2008;102(10):1239–46.
Ghavami S, Rashedi I, Dattilo BM, Eshraghi M, Chazin WJ, Hashemi M, et al. S100A8/A9 at low concentration promotes tumor cell growth via RAGE ligation and MAP kinase-dependent pathway. J Leukocy Biol. 2008;83(6):1484–92.
Hiratsuka S, Watanabe A, Sakurai Y, Akashi-Takamura S, Ishibashi S, Miyake K, et al. The S100A8–serum amyloid A3–TLR4 paracrine cascade establishes a pre-metastatic phase. Nat Cell Biol. 2008;10(11):1349–55.
Markowitz J, Carson WE. Review of S100A9 biology and its role in cancer. Biochim Biophys Acta (BBA) Rev Cancer. 2013;1835(1):100–9.
Kerkhoff C, Sorg C, Tandon NN, Nacken W. Interaction of S100A8/S100A9—arachidonic acid complexes with the scavenger receptor CD36 may facilitate fatty acid uptake by endothelial cells. Biochemistry. 2001;40(1):241–8.
Kerkhoff C, Klempt M, Kaever V, Sorg C. The two calcium-binding proteins, S100A8 and S100A9, are involved in the metabolism of arachidonic acid in human neutrophils. J Biol Chem. 1999;274(46):32672–9.
Sopalla C, Leukert N, Sorg C, Kerkhoff C. Evidence for the involvement of the unique C-tail of S100A9 in the binding of arachidonic acid to the heterocomplex S100A8/A9. Biol Chem. 2002;383(12):1895–905.
Lim SY, Raftery MJ, Goyette J, Hsu K, Geczy CL. Oxidative modifications of S100 proteins: functional regulation by redox. J Leukocy Biol. 2009;86(3):577–87.
Kerkhoff C, Nacken W, Benedyk M, Dagher MC, Sopalla C, Doussiere J. The arachidonic acid-binding protein S100A8/A9 promotes NADPH oxidase activation by interaction with p67phox and Rac-2. FASEB J. 2005;19(3):467–9.
Benedyk M, Sopalla C, Nacken W, Bode G, Melkonyan H, Banfi B, et al. HaCaT keratinocytes overexpressing the S100 proteins S100A8 and S100A9 show increased NADPH oxidase and NF-κB activities. J Investig Dermatol. 2007;127(8):2001–11.
Ichikawa M, Williams R, Wang L, Vogl T, Srikrishna G. S100A8/A9 activate key genes and pathways in colon tumor progression. Mol Cancer Res. 2011;9(2):133–48.
Zhong JM, Li J, Kang AD, Huang SQ, Liu WB, Zhang Y, et al. Protein S100-A8: a potential metastasis-associated protein for breast cancer determined via iTRAQ quantitative proteomic and clinicopathological analysis. Oncol Lett. 2018;15(4):5285–93.
Srikrishna G. S100A8 and S100A9: new insights into their roles in malignancy. J Innate Immun. 2012;4(1):31–40.
Rajendran P, Chen YF, Chen YF, Chung LC, Tamilselvi S, Shen CY, et al. The multifaceted link between inflammation and human diseases. J Cell Physiol. 2018;233(9):6458–71.
Lim SY, Yuzhalin AE, Gordon-Weeks AN, Muschel RJ. Tumor-infiltrating monocytes/macrophages promote tumor invasion and migration by upregulating S100A8 and S100A9 expression in cancer cells. Oncogene. 2016;35(44):5735–45.
Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010;141(1):52–67.
Cormier K, Harquail J, Ouellette RJ, Tessier PA, Guerrette R, Robichaud GA. Intracellular expression of inflammatory proteins S100A8 and S100A9 leads to epithelial-mesenchymal transition and attenuated aggressivity of breast cancer cells. Anti Cancer Agents Med Chem (Former Curr Med Chem Anti Cancer Agents). 2014;14(1):35–45.
Zheng Y, Hou J, Peng L, Zhang X, Jia L, Wang Xe, Wei S. H. Meng. The pro-apoptotic and pro-inflammatory effects of calprotectin on human periodontal ligament cells. PLoS One. 2014;9(10):e110421.
Ghavami S, Kerkhoff C, Chazin WJ, Kadkhoda K, Xiao W, Zuse A, et al. S100A8/9 induces cell death via a novel, RAGE-independent pathway that involves selective release of Smac/DIABLO and Omi/HtrA2. Biochimica et Biophysica Acta (BBA)-Molecular. Cell Res. 2008;1783(2):297–311.
Najafi M, Alizadeh SA, Azad M, Farivar TN, Rajaei F, Sorouri KH, et al. Effect of calprotectin subunit S100A9 on the expression and methylation of OCLN in human melanoma cell line A-375. Turk J Biol. 2017;41:849–56.
Sattari M, Pazhang Y, Imani M. Calprotectin induces cell death in human prostate cancer cell (LNCaP) through survivin protein alteration. Cell Biol Int. 2014;38(11):1311–20.
Acknowledgements
This work was supported by the Deputy of Research and Technology, Qazvin University of Medical Sciences., Qazvin, Iran.
Funding
The authors declare no financial relationships relevant to this article to disclose.
Author information
Authors and Affiliations
Contributions
All authors contributed equally in this work.
Corresponding author
Ethics declarations
Conflict of interest
The authors have no conflicts of interest to declare.
Additional information
Responsible Editor: John Di Battista.
Rights and permissions
About this article
Cite this article
Shabani, F., Farasat, A., Mahdavi, M. et al. Calprotectin (S100A8/S100A9): a key protein between inflammation and cancer. Inflamm. Res. 67, 801–812 (2018). https://doi.org/10.1007/s00011-018-1173-4
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00011-018-1173-4